Remove Competition Remove Insurance Remove Patients Remove Prescription
article thumbnail

PBMs and insurers want your prescription money

World of DTC Marketing

anti-kickback law that the drugmaker said prevented it from helping heart failure patients, many with low incomes, afford the medicine that costs $225,000 annually. For many, these coupons represent the difference between filling a prescription and going without lifesaving care, but there is a lot more here than just a co-pay coupon.

Insurance 226
article thumbnail

 The US accounts for more than 40% of all health spending.

World of DTC Marketing

Most Americans don’t have much of a choice for their insurance plan. Mor than 54 % get health insurance through their employer. The lack of choice limits competition, which can drive prices higher. According to KFF, “ the cost of health care often prevents people from getting needed care or filling prescriptions.

Insurance 154
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Market Access Disruption—How New Generic Players Are Changing the Game

PM360

Simplicity seems to be the aim here, by providing a fixed monthly price consumers don’t need to compare pharmacy prices or discern their insurance copay. Both programs list price information for the medications they provide, demonstrating the average savings based on retail and insurance prices.

article thumbnail

8 Ways to Enhance the Patient Experience & Drive Leads with QR Codes

Healthcare Success

The QR code allows hospitals and healthcare providers to satisfy this need with immediate physician-patient interaction and engagement – all through smartphones and tablets. . Ready to start leveraging QR code technology and stay ahead of your competition? QR codes are also proving valuable for storing confidential patient information.

Leads 109
article thumbnail

Consequences of the First 10 Drugs Selected for Medicare’s Negotiation Program

PM360

As many in the industry now know, the Inflation Reduction Act (IRA) is the most significant reform of Medicare prescription drug coverage since the creation of Part D and has wide-ranging implications for the healthcare industry. They do not have biosimilar or generic competition available in the market.

article thumbnail

Two Key Questions About Payer Strategies in 2023

PM360

However, we expect drugs without strong therapeutic alternatives to have an advantage in negotiations, while drugs in highly competitive classes will be negotiating from a weaker position. The business-to-business market leaders must find new and creative ways to help patients receive their treatments. The 340B battle will rage on.

article thumbnail

The AMJEVITA impact: Innovative U.S. biosimilar pricing models

Clarivate

The Biosimilars Forum has hailed 2022 as a watershed year that could create a more competitive U.S. biologics market and reduce prescription drug costs. The larger discount will be available to insurers who choose not to utilize those discounts and rebates. from 91% in 2023 to 36% by 2031.